MA32_snp_data.csv (128.8 kB)

Metadata record for the article: Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial

dataset

posted on 2021-05-13, 08:49 authored by Pamela J. Goodwin, Ryan J.O. Dowling, Marguerite Ennis, Bingshu E. Chen, Wendy R. Parulekar, Lois E. Shepherd, Margot J. Burnell, Rachel VanderMeer, Andrea Molckovsky, Anagha Gurjal, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Whelan, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Julie Lemieux, Alistair M. Thompson, Daniel W. Rea, Vuk Stambolic

Summary

This metadata record provides details of the data supporting the claims of the related article: “Effect of Metformin versus Placebo on Metabolic Factors in the MA.32 Randomized Adjuvant Breast Cancer Trial”.

The related study examined metformin impact on metabolic factors in non-diabetic subjects to determine whether this impact varies by baseline BMI, insulin and rs11212617 SNP in CCTG MA.32, a double-blind placebo controlled randomised adjuvant breast cancer (BC) trial.

Type of data: single-nucleotide polymorphism (SNP); clinical data

Subject of data: Homo sapiens

Sample size: 2915

Population characteristics: See Table 1 of the related article

Trial registration number: http://clinicaltrials.gov/show/NCT01101438

Data access

The SNP data are openly available as part of this figshare metadata record in the file ‘MA32_snp_data.csv’.

The primary efficacy analysis will be available from the Canadian Cancer Trials Group (Kingston, Ontario) after the results of the analysis have been published. These data will be uploaded to the NCI data archive website: https://nctn-data-archive.nci.nih.gov/view-trials and will be searchable via NCT trial number NCT01101438. As of April 2021, the group is working towards this publication. Further details can be requested from the corresponding author.

The clinical data are not publicly available for the following reason: data contain information that could compromise research participant privacy.

Corresponding author(s) for this study

Dr. Pamela J. Goodwin, Mount Sinai Hospital, 1085-600 University Avenue, Toronto, Ontario M5G 1X4. Tel: 416-586-8211. Fax: 416-586-3199. Email: Pamela.Goodwin@sinaihealthsystem.ca.

Study approval

The study protocol was approved by institutional review boards of participating institutions, including the NCI (US) Central Institutional Review Board and Mount Sinai Hospital (Ontario Cancer Research Ethics Board).

Funding

Canadian Cancer Society Research Institute (Société Canadienne du Cancer) - 021039 [Goodwin] U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) - CA077202, CA180868, CA180822 [Goodwin] Ontario Institute for Cancer Research (Institut Ontarien de Recherche sur le Cancer) - 10NOV-467 [Goodwin] Breast Cancer Research Foundation (BCRF) - Multiple grants [Goodwin] Apotex Pharmaceuticals (Canada) - Funding in kind (metformin, placebo) - no grant #, Hold'Em for Life Charity (Canada) - no grant # [Goodwin] Canadian Breast Cancer Foundation (Fondation Canadienne du Cancer du Sein) - xxx [Parelukar] Ontario Institute for Cancer Research (Institut Ontarien de Recherche sur le Cancer) - 10NOV-467 [Stambolic]

History

Research Data Support

This record was produced by Springer Nature’s Research Data Support service. This service focuses on maximising the findability and accessibility of the data, and does not involve peer review of data.